Key result
SUNRISE registry evaluates Suhexiang pill effectiveness for 3-month functional independence after acute ischemic stroke.
Why the study?
Does Suhexiang pill improve functional independence at 3 months in patients with acute ischemic stroke?
Observational (n=1,000)
Yes
Does Suhexiang pill improve functional independence at 3 months in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
The SUNRISE registry protocol outlines a prospective observational study to evaluate the real-world effectiveness and safety of the Suhexiang pill in acute ischemic stroke.
BACKGROUND: Suhexiang (SHX) pill is widely used for treating acute ischemic stroke (AIS). Experimental and randomized controlled trials suggested that SHX pill was beneficial for patients with AIS. However, the effectiveness of SHX pill in real-world practice setting remains unclear. It is of great importance to investigate the effectiveness and safety of SHX pill in patients with acute ischemic stroke in real-world clinical practice with long-term follow-up. METHODS: The Suhexiang pill for acute ischemic stroke in Real-world Practice Setting (SUNRISE) is a multicenter, prospective, product-specific, observational study designed to provide insight into the administration of SHX pill for patients with AIS in the real-world clinical practice setting, with an initial sample size of 1000. Eligible patients treated with SHX pill within seven days of AIS onset will be consecutively included in this registry. The primary outcome is the proportion of patients independent at 3 months after stroke onset defined by an mRS score of 0, 1, or 2. CONCLUSION: The findings of the SUNRISE registry will not only provide insights into the characteristics of patients who may benefit from SHX treatment, but also may enable the individualized treatment decision-making of SHX pill in real-world practice setting. STUDY REGISTRATION: This study was registered with the ClinicalTrials.gov (URL: https://clinicaltrials.gov/ , Unique identifier: NCT05833932).
No takes yet. Share an insight, caveat, or question.
Lai et al. (2025) conducted an observational in Acute ischemic stroke (n=1,000). Suhexiang (SHX) pill was evaluated on Proportion of patients independent at 3 months after stroke onset defined by an mRS score of 0, 1, or 2. The SUNRISE registry is a protocol for a multicenter, prospective observational study designed to evaluate the real-world effectiveness of the Suhexiang pill in 1,000 patients with acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: